| abstract |
Disclosed are compositions comprising chimeric antigen receptors (CARs) and related methods of use in cancer immunotherapy. Compositions include reprogrammed immune cells (e.g., macrophages, neutrophils, dendritic cells, and T cells) that are metabolically fit for tumor microenvironments. The engineered immune cells are reprogrammed to express one or more of recombinant CARs at their cell surfaces and are loaded with glycolysis accelerating metabolites (e.g., F16BP or succinate). Methods of treating a subject with a condition, such as cancer, are also disclosed and include administering an effective amount of a composition comprising an engineered immune cell to a subject in need thereof. |